- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07620002
Nociception Level Index After Brachial Plexus Block In Upper Extremity Surgery
26. mai 2026 oppdatert av: Michael Grach, Carmel Medical Center
Nociception Level Index After Brachial Plexus Block In Upper Extremity Surgery: Prospective Comparison Trial
The present prospective within-subject observational study will evaluate whether unilateral brachial plexus block (BPB) induces measurable lateralized autonomic modulation, assesses using bilateral Nociception Level (NoL) monitoring during standardized intraoperative stimuli under general anesthesia.
Regional anesthesia efficacy is traditionally assessed through sensory and motor examination.
However, objective physiologic markers reflecting sympathetic modulation remain limited.
Forty five adults undergoing upper extremity surgery with BPB and general anesthesia, bilateral NoL monitoring will be performed during local anesthetic injection, endotracheal intubation, and nasogastric tube placement.
The primary aim to investigate whether the brachial plexus block induces unilateral modulation of post-operative nervous system activity, assessed by inter-limb differences in NoL values during predefined nociceptive stimuli under general anesthesia.
The secondary aim to evaluate the correlation between postoperative metrics, postoperative pain intensity, and analgesic consumption.
From a clinical perspective, bilateral autonomic monitoring may offer a novel adjunctive method for intraoperative confirmation of block activity, particularly in sedated or anesthetized patients where traditional sensory testing is not feasible.
Furthermore, inter-limb autonomic gradients could represent a future research pathway for objective assessment of regional anesthesia effectiveness beyond subjective pain scores.
Studieoversikt
Status
Rekruttering
Forhold
Detaljert beskrivelse
The hypotheses is that brachial plexus block (BPB) would induce an ipsilateral reduction in SANS activity compared to the contralateral side.
The study intervention involved the standard administration of the BPB, a low-risk perineural injection of local anesthetics, conducted under real-time ultrasound guidance and monitored using NoL score measurements on both hands concurrently during endotracheal intubation.
An ultrasound-guided single-shot BPB will be performed using 10 mL of 0.5% bupivacaine (50 mg) in all patients.
The study duration for each participant approximately 5 hours.
All participants undergo induction of general anesthesia using a standardized regimen: midazolam 0.025 mg/kg and fentanyl 0.25 mcg/kg prior to BPB, followed by propofol 2.5 mg/kg, fentanyl 0.75-1 mcg/kg, and rocuronium 0.7 mg/kg.
Subsequently, participants will be intubated (including nasogastric tube placement) and ventilated with maintenance inhalational anesthetics, supplemented by continuous intravenous administration of the short-acting opioid remifentanil at doses of 30-70 ng/kg/min, adjusted according to hemodynamic parameters.
Block efficacy will be assessed using postoperative pain (visual analog scale (VAS)), analgesic consumption, intraoperative analgesic consumption, and NoL measurements in the non-operated hand.
In instances of suboptimal or failed block, all patients in this study will be provided with a backup perioperative analgesic regimen involving continuous intravenous administration of short-acting opioids and remifentanil at doses of 30-70 ng/kg/min .Safety assessments• Pre-anesthetic evaluation and eligibility for general and regional anesthesia• Standard monitoring will be performed according to the American Society of Anesthesiologists (ASA) o Pulse oximetry o Non-invasive blood pressure repeated measurement so 5-lead ECGo End tidal CO2• The principal investigator will assess adverse and serious adverse events, including identification, follow-up, documentation, and reporting to the IRB.
Statistical analysis Primary Endpoint: The statistical null hypothesis posited that there would be no spatial differences in the NoL score measurements following BPB.
Conversely, hypothesized that patients undergoing upper extremity surgery would exhibit lower ipsilateral hand NoL scores than the contralateral hand during noxious stimulation after BBP.
Secondary Endpoints: The null hypothesis proposed that there would be no correlation between the NoL score measurements post-BPB and postoperative pain levels.
Alternative hypothesis that a correlation exists between the contralateral hand NoL scores and postoperative pain levels in patients undergoing upper extremity surgery after BPB.
Sample Size Determination Sample size calculation based on the primary endpoint, defined as the paired difference in NoL values between the blocked (ipsilateral) and contralateral limbs during endotracheal intubation.
Based on preliminary observations and previously reported NoL variability, it is assumed that an expected mean paired difference of approximately 7 units, with a standard deviation of paired differences of 8 units.
Using a two-sided paired t-test with a significance level (alpha) of 0.05 and a statistical power of 80%, a minimum of 34 evaluable subjects will be required.
To account for potential exclusions and incomplete data, 45 participants are planned for enrollment.
Statistical analysis This study will employ a prospective within-subject comparison design.
Continuous variables will be presented as mean ± standard deviation, and categorical variables presented as counts and percentages.
A pragmatic sample size was chosen based on the feasibility of previous NoL studies using within-subject designs.
The study aims to enroll 45 patients to allow paired comparisons between the blocked and contralateral limbs during predefined nociceptive stimuli.
The primary analysis based on paired comparisons of within-subject differences in NoL values between the blocked (ipsilateral) and non-blocked (contralateral) hands for each predefined stimulus (brachial plexus block injection, endotracheal intubation, and nasogastric tube placement).
NoL index measured by a non-invasive probe attached to the index finger (in both arms, the operated hand and the contralateral unoperated arm as control) using an adhesive patch.
The device manufactured by Medasense (Ramat Gan, Israel).
The monitoring module model PMD-200.
The device is indicated for assessing pain levels in unconscious patients.
Paired t-tests were used for the comparisons.
Secondary exploratory analyses will evaluate the correlations between aggregated intraoperative NoL exposure, expressed as the percentage of total monitoring time spent within predefined NoL ranges (lower than 10, 10-25, and higher than 25), and postoperative pain outcomes, including VAS scores and analgesic consumption.
Pearson's correlation coefficients will be calculated for these analyses.
All statistical tests two-sided, and a P value <0.05 will be considered statistically significant.
Variables Independent variables: discrete variable• gender (male/female)• operated hand (left/right)continuous variables:• age (years)• weight (kg)• height (cm)• ASA score Dependent variables: discrete variables• VAS (1-10) continuous variables Anesthesia induction times (HH:MM)• Patient entering the room • Performing BPB • Performing intubation post operative• Nasogastric tube• Induction completed• Surgery and recovery times (HH:MM)• Surgery start• Surgery end• Transfer to Post Anesthetic Care Unit (PACU)• Discharge from PACU• NoL levels difference between right- and left-hands during anesthesia induction• Peak levels differences (NoL index values)• After BPB• After intubation• After nasogastric tube placement• Time of peak levels differences (seconds)• After BPB• After intubation• After nasogastric tube placement• Left-right difference between duration of NoL index higher than 25 (seconds)• NoL levels in non-operated hand from patient entering the operating room to discharge from the PACU (NoL index values temporal variations)• Total time of NoL index higher than 25 (min)• Total time of NoL index between 10-25 (min)• Total time of NoL index lower than 10 (min)• Analgetic treatment • Perioperative total Remifentanil consumption (mg)• Post operative Morphine consumption (mg)• Peri and post operative Non-Steroidal-Anti-Inflammatory Drugs (NSAIDs) consumption• Paracetamol (g)• Ketorolac (mg)• Dipyrone (g)
Studietype
Observasjonsmessig
Registrering (Antatt)
45
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Michael Grach, DR.
- Telefonnummer: +972506265753
- E-post: Grachm@gmail.com
Studer Kontakt Backup
- Navn: Dana Kosh, Dr.
- Telefonnummer: 972-48250785
- E-post: danak@clalit.org.il
Studiesteder
-
-
-
Haifa, Israel, 3436212
- Rekruttering
- Carmel Medical Center
-
Ta kontakt med:
- Dana Kosh, Dr.
- Telefonnummer: 972-48250785
- E-post: danak@clalit.org.il
-
Ta kontakt med:
- Michael Grach, Dr.
- Telefonnummer: 972506265753
- E-post: Grachm@gmail.com
-
Hovedetterforsker:
- Michael Grach, Dr.
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Ja
Prøvetakingsmetode
Sannsynlighetsprøve
Studiepopulasjon
forty five patients over 18 years old meeting inclusion criteria
Beskrivelse
Inclusion Criteria:
- Age >18
- Upper extremity surgery
- Provision of signed and dated informed consent forms
Exclusion Criteria:
- Pregnant women
- Known allergic reaction to bupivacaine or other anesthetic medicine: Midazolam, Fentanyl, Propofol, Rocuronium, Remifentanil, Sevoflurane)
- Known coagulopathy resulting in bleeding tendency
- Thrombocytopenia
- Abnormal laboratory coagulation tests in the previous week = Anticoagulation therapy Participation in other study
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
patient both arms: one operated under brachial plexus block, other serves only as control;
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Comparison ipsilateral and contralateral NoL values in both arms
Tidsramme: five hours
|
Perioperative NoL score every 5 seconds (physiological parameter measurements, range 0-100) on both arms concurrently, begin before anesthesia induction, till patient will be discharged from PACU, by a non-invasive probe attached to the index finger (in both arms, the operated hand and the contralateral unoperated arm as control) using an adhesive patch.
The device monitoring module model PMD-200 manufactured by Medasense (Ramat Gan, Israel).
|
five hours
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Perioperative pain Assessments and correlations between NoL and VAS values
Tidsramme: five hours
|
Perioperative pain outcomes, VAS scores by questionnaires, range 1-10 at 3 time points: preoperative, post brachial plexus block and discharge from PACU.
Correlations between VAS and NoL physiological parameter measurements, range 0-100, by a non-invasive probe attached to the index finger (in both arms, the operated hand and the contralateral unoperated arm as control) using an adhesive patch at parallel time points.
Monitoring module model PMD-200 the device manufactured by Medasense (Ramat Gan, Israel).
|
five hours
|
|
Perioperative correlations between total analgesic consumption with VAS and with NoL values
Tidsramme: Five hours
|
Perioperative correlations between total analgesic consumption with VAS and with NoL values:
|
Five hours
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
28. mars 2023
Primær fullføring (Antatt)
30. september 2026
Studiet fullført (Antatt)
30. september 2026
Datoer for studieregistrering
Først innsendt
10. mai 2026
Først innsendt som oppfylte QC-kriteriene
26. mai 2026
Først lagt ut (Faktiske)
2. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
2. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
26. mai 2026
Sist bekreftet
1. mars 2026
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 0110-22-CMC
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
IPD-planbeskrivelse
Afer completion of study and publication, data may be concidered to be shared
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .